SGP net incomeQ2 2026-$19.86M
SGP net income was -$19.86M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$8.68M a year earlier. For the full fiscal 2025 it was -$39.87M, compared with -$29.16M in fiscal 2024.
SpyGlass Pharma Inc. (SGP) financials
For fiscal 2025 (ended Dec 31, 2025), SpyGlass Pharma Inc. reported -$39.87M of net income.
- Net income, FY2025
- -$39.87M
- Free cash flow, FY2025
- -$33.49M
- EPS, diluted, FY2025
- -$17.98
- Cash
- $223.14M
- Market cap
- $1.28B
FY2024FY2025
FY2024FY2025
SGP revenue and earnings growth
SGP EPSQ2 2026-$0.59
SGP diluted EPS was -$0.59 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$17.98, compared with -$16.31 in fiscal 2024.
SGP free cash flowQ2 2026-$16.77M
SGP free cash flow was -$16.77M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$6.38M a year earlier. For the full fiscal 2025 it was -$33.49M, compared with -$24.02M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Research and development | $29.18M | $19.98M |
| Selling, general and admin | $12.27M | $7.08M |
| Operating income | -$41.45M | -$27.06M |
| Pre-tax income | -$39.87M | -$29.16M |
| Income tax | $0 | $0 |
| Net income | -$39.87M | -$29.16M |
| EPS, basic | -$17.98 | -$16.31 |
| EPS, diluted | -$17.98 | -$16.31 |
| Diluted shares | 2.2M | 1.8M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Cash and equivalents | $96.36M | $16.27M |
| Current assets | $108.77M | $17.41M |
| Total assets | $115.87M | $23.32M |
| Current liabilities | $8.58M | $7.79M |
| Total liabilities | $10.17M | $11.25M |
| Shareholders' equity | -$98.84M | -$60.47M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Operating cash flow | -$32.70M | -$22.03M |
| Capital expenditures | $789.0K | $1.99M |
| Free cash flow | -$33.49M | -$24.02M |
| Investing cash flow | -$11.79M | $22.26M |
| Financing cash flow | $124.58M | $185.0K |
| Share repurchases | $1.45M | $0 |
| Stock-based compensation | $2.79M | $1.49M |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Jun 30, 2025 | Mar 31, 2025 |
|---|---|---|---|---|
| Research and development | $10.94M | $8.54M | $7.33M | $6.05M |
| Selling, general and admin | $11.03M | $6.87M | $1.96M | $1.37M |
| Operating income | -$21.97M | -$15.41M | -$9.30M | -$7.42M |
| Pre-tax income | -$19.86M | -$13.82M | -$8.68M | -$8.82M |
| Income tax | $0 | $0 | $0 | $0 |
| Net income | -$19.86M | -$13.82M | -$8.68M | -$8.82M |
| EPS, basic | -$0.59 | -$0.69 | -$3.81 | -$3.96 |
| EPS, diluted | -$0.59 | -$0.69 | -$3.81 | -$3.96 |
| Diluted shares | 33.4M | 19.9M | 2.3M | 2.2M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Jun 30, 2025 | Mar 31, 2025 |
|---|---|---|---|---|
| Cash and equivalents | $223.14M | $238.90M | $127.23M | $58.00M |
| Current assets | $236.46M | $253.36M | - | - |
| Total assets | $243.43M | $258.39M | - | - |
| Current liabilities | $9.44M | $6.67M | - | - |
| Total liabilities | $11.07M | $8.27M | - | - |
| Shareholders' equity | $232.36M | $250.11M | -$78.38M | -$68.85M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Jun 30, 2025 | Mar 31, 2025 |
|---|---|---|---|---|
| Operating cash flow | -$14.84M | -$13.54M | -$6.33M | -$8.20M |
| Capital expenditures | $1.93M | $676.0K | $52.0K | $164.0K |
| Free cash flow | -$16.77M | -$14.22M | -$6.38M | -$8.37M |
| Investing cash flow | -$933.0K | -$1.67M | -$52.0K | -$164.0K |
| Financing cash flow | $13.0K | $157.75M | $75.61M | $50.10M |
| Stock-based compensation | $2.08M | $1.68M | $587.0K | $345.0K |
Key ratios
Source: XBRL data SpyGlass Pharma Inc. files with the SEC, latest filing dated Aug 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
SGP peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| SGP | - | - | -$39.87M | - | $1.28B |
| SYK | $26.30B | +7.9% | $3.62B | 13.8% | $124.00B |
| MMM | $25.25B | +1.7% | $3.54B | 14.0% | $97.47B |
| BSX | $21.07B | +8.9% | $3.50B | 16.6% | $63.81B |
| BDX | $23.25B | +17.4% | $941.00M | 4.0% | $58.63B |
| MDLN | $30.68B | - | $683.00M | 2.2% | $53.55B |
| RMD | $5.73B | +9.0% | $1.59B | 27.8% | $33.16B |
| DXCM | $5.10B | +13.0% | $991.00M | 19.4% | $30.24B |
| WST | $3.40B | +12.6% | $638.90M | 18.8% | $28.78B |
SGP FAQ
6 questionsIs SGP profitable?
No. SpyGlass Pharma Inc. reported a net loss of $39.87M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does SGP have?
SpyGlass Pharma Inc. reported $223.14M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is SGP free cash flow?
SpyGlass Pharma Inc. generated -$33.49M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$32.70M less capital expenditures.What is SGP earnings per share?
Diluted earnings per share were -$17.98 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did SGP last report financial results?
The latest statements here come from SpyGlass Pharma Inc.'s 10-Q filed on Aug 6, 2026, covering the period ended Jun 30, 2026.Where does this SGP financial data come from?
Quantisnow builds these statements from the structured XBRL data SpyGlass Pharma Inc. files with the SEC. It is provided for information only and is not investment advice.